Table 3 IGSF11 and VISTA targeted drugs

Gastric cancer

IGSF11

Polypeptide Vaccine

Enhance the Function of CTLs

16,108,831

Melanoma

IGSF11

SG7

Inhibit the interaction between VISTA and IGSF11

32,938,950

Colon Carcinoma

IGSF11/PD1

SG7 combined with anti-PD1

Inhibit the interaction between VISTA and IGSF11; anti-PD1

32,938,950

Colon Carcinoma

VISTA/PD-L1

VISTA-Ig and PD-L1 Ig

anti-VISTA and anti-PD-L1

25,964,334

Enhance the response of T cells

Increase the count of T cells

Boost antigen presentation

Advanced Solid Tumors or Lymphomas

VISTA/KRAS

CA170 and KRAS peptide vaccine

Boost the infiltration of CD8 + T cells

34,302,042

Decrease the infiltration of MDSCs

Decrease the infiltration of Tregs

Inhibit lung tumorigenesis

Solid tumor

VISTA

CI-8993

anti-VISTA

33,937,071

Melanoma

VISTA

13F3

Inhibit the proliferation of tumor

24,691,994

Induce the apoptosis of tumor cells

Increase the count of IFN-γ producing cells

Promote the response of tumor specific T cells

Melanoma

VISTA

αVISTA

Increase the count of CD4 + and CD8 + T cells

24,691,994

Decrease the infiltration of MDSCs

Bladder tumor

VISTA

13F3

Activate tumor-associated CD11c + DCs

24,691,994

Induce the production of IL-12 and TNF-α

Decrease the count of Foxp3GFP + iTregs

Directly inhibit Tregs activation

Enhance the proliferation and cytotoxic function of CD8 + T cells

Mouse model

VISTA

6809–0223

Promote the proliferation of CD4 + T cell

34,380,434

Induce the production of IL-2 from both CD4 + and CD8 + T cell

Induce the production of IL-4, IFN-γ and TNF-α from CD8 + T cell

Colon cancer

VISTA

HMBD-002

Promote the response of proinflammatory Th1 cells

35,131,861

Breast cancer

Increase the number of CD11b + macrophages, CD11c + DCs and CD8 + T cells

Colorectal cancer

Lung cancer

Squamous cell carcinoma

VISTA/CTLA4

MIH63

Activate and upregulate CD8 + T cells

34,282,763

Converse the exhausted cells into

effector CD8 + T cells

27,208,845

Promote the secretion of TNF- α and IFN-γ